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TUMOURS appear, as a general rule, to possess many, but not necessarily all,
of the antigens present in the normal tissues of the individual in which they
arise. They may in addition possess antigens which are not present in normal
tissues. Clinical evidence pointing in this direction is provided by the slow
progress ofsome tumours and the occasional occurrence ofspontaneous remissions
(Ewing, 1941; Barrett, 1955), by the occurrence of " reactive hyperplasia "
in lymph nodes in the vicinity of a tumour (Black and Speer, 1959), and by
recent observations in whicti the injection of material from a patient's own
tumour homogenized in Freund's adjuvant has resulted in a rise in the titre of
antibody capable of reacting in some way with tumour extracts (Finney, Byers
and Wilson, 1960). Experimental evidence of the occurrence of tumour-specific
antigens has been obtained in the case of some chemically induced tumours
(Prehn and Main, 1957; Revesz, 1960; Stern, 1960) and, while similar experi-
ments with spontaneous animal tumours have for the most part yielded negative
results, Woodruff and Symes (1962a, b) have recently obtained evidence that
spontaneous A-strain mammary carcinomata are antigenic in the animals in
which they arise, though they cease to be so after being transplanted repeatedly
in animals ofthe same strain.
In so far as a tumour does possess antigens lacking in the normal tissues ofits
host* it is open to immunological attack. It is conceivable that some tumours
are destroyed in this way before their existence is suspected, but it is clear that
those which survive either fail to evoke a strong immune response or develop a
high degree of invulnerability. Various reasons may be suggested to account
for this. On the one hand the tumour-specific antigens may be " weak ", may be
liberated in insufficient quantity to immunize, or may be deleted before the
immunological defences have succeeded in destroying the tumour. Alternatively,
so much antigen may be liberated that the host becomes specifically unresponsive,
or there may be generalized impairment of immunological efficiency due to
cachexia occasioned by the tumour or widespread replacement oflymphoid tissue
by metastases.
It would seem likely that tumours which are effectively antigenic in their
hosts evoke the same kind of reaction as homografts, and, since the fate of a
homograft often turns on whether or not it comes into effective contact with im-
munologically competent host cells (for review see Woodruff, 1960), it is curious
that attempts to forge immunological weapons against cancer have been so
largely confinedto thesearchfortumour-specific sera, andnot altogether surprising
that this work has so far proved rather unrewarding.
* The term host is used to denote animals or humans bearing spontaneous tumours as well as
animals which have received tumour transplants or in which tumours have been chemically induced.M. F. A. WOODRUFF AND M. 0. SYMES
Another approach, which is suggested by the phenomenon of adoptive im-
munization (Mitchison, 1955; Billingham, Brent and Medawar, 1956; Koller
and Doak, 1959; Billingham and Silvers, 1961), is to try to destroy a tumour by
injecting into the host immunologically competent cells from a donor of the same
genetic constitution which has been immunized by transplanting a piece of the
tumour and then destroying it in situ by repeatedly ligating its vascular con-
nections (Lewis and Aptekman, 1952; Foley, 1958; Prehn, 1960). It has been
shown by Koldovsky and his colleagues that the survival ofA-strain mice receiving
transplants ofSarcoma I and other tumours may be prolonged in this way provided
that the treatment coincides with or precedes transplantation of the tumour (Koldovsky and Lengerova', 1960; Koldovsky, 1961) or, if given later, is com-
bined with irradiation (Koldovsky and Lengerova', 1960) or surgical excision of
the tumour (Koldovsky, 1962). The procedure is however subject to two limita-
tions. In the first place it is applicable experimentally only to animals which
are members of a genetically uniform strain, and could be used clinically only if
the patient possessed an identical twin who was not suffering from the same type
of tumour. Secondly, it can only be effective against tumours which still retain
specific antigens and, as Woodruff and Symes (1962b) have shown, deletion of such
antigens appears to be one of the mechanisms by which tumours escape from
control.
A third type of procedure, which is not necessarily limited in either of these
ways, is suggested by the discovery of the graft-versus-host reaction.
This phenomenon, which was first clearly recognized by Billingham and
Brent (1957), occurs when immunologically competent cells are transplanted to a
recipient possessing one or more transplantation antigens not represented in the
donor and which for some reason is unable to destroy the transplanted cells
sufficiently quickly to render them innocuous.
The severity of the graft-versus-host reaction depends inter alia on (a) the
antigenic constitution of donor and host, (b) whether or not the donor has been
pre-immunized against the tissues of the host, (c) the number of immunologically
competent cells injected, and (d) the extent to which the capacity of the host to
provide an environment which is congenial to the transplanted cells in respect of
both immunological and non-immunological factors is modified by irradiation
and other forms of treatment. In addition, there is evidence that in both new-
born (Russell, 1962) and irradiated adult (Woodruff, 1962) mice, the course of the
disease may be influenced by subsequent administration of A-methopterin or
isogeneic immunologically competent cells.
It seems reasonable to postulate that the effect of foreign immunologically
competent cells on a tumour will depend on (a) the antigenic constitution of the
tumour-bearing host and the cell donor, (b) the difference, if any, in antigenic
structure of the tumour and the normal tissues of the host, (c) whether or not the
donor has been immunized against antigens belonging to the tumour, (d) the
number of immunologically competent cells gaining access to the tumour, and
(e) the time for which these cells are able to react against it.
There is already evidence that an immunological reaction mediated by the
transplanted cells may contribute to the destruction of transplantable leukaemia
in mice treated by lethal or supralethal irradiation and homotransplantation of
bone marrow or splenic tissue (Barnes, Corp, Loutit and Neal, 1956; Barnes,
Corp, Ilbery, Loutit and Neal, 1959; Barnes and Loutit, 1957; Math6 and
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Bernard, 1959a, b; Math6, 1960), but mice whose leukaemia was eradicated in
this way subsequently died of graft-versus-host disease. Despite this, Mathe
and his colleagues (Math6, Bernard, Schwarzenberg, Larrieu, Lalanne, Dutreix,
Denoix, Surmont, Schwarzmann and C6orara, 1959; Mathe, Bernard, De Vries,
Schwarzenberg, Larrieu, Lalanne, Dutreix, Amiel and Surmont, 1960; Mathe,
1960) have attempted to treat human leukaemia by the same method; their
patients all died however as a result of marrow aplasia, graft-versus-host disease
or recurrence of the leukaemia.
We have set out to investigate the transplantation of allogeneic immunologic-
ally competent cells in the treatment of solid tumours, which would seem to
offer more scope than the leukaemias for attempts to direct the attack in such a
way as to produce the maximal effect on the tumour with the minimum ofdamage
to the host.
MATERIALS AND METHODS
General plan of the experiments
In the basic experiment adult A-strain mice ofeither sex received a transplant
of an A-strain mammary carcinoma* by the technique described previously
(Woodruff and Symes, 1962a). Starting five days later all the recipients, apart
from some set aside as untreated controls, received one of the following forms
of treatment:
(1) 400 r whole body irradiation.
(2) 400 r whole body irradiation followed immediately by a single intravenous
injection ofnormal isogeneic (A-strain) spleen cells.
(3) 400 r whole body irradiation followed by one or more intravenous injec-
tions of normal allogeneic (CBA strain) spleen cells.
(4) 400 r whole body irradiation and injection ofnormal allogeneic spleen cells,
followed by a course of treatment with A-methopterin.
(5) 400 r whole body irradiation followed by one or more intravenous injec-
tions of lymph node and/or spleen cells from CBA mice which had previously
been immunized by transplants of the A-strain tumour.
(6) 400 r whole body irradiation and injection of pre-immunized lymph node
and/or spleen cells, followed by a course of treatment with A-methopterin.
Every third day the animals were weighed to the nearest 0-1 g. and the
diameter of the tumour transplants was measured with a calliper to the nearest
mm. in two directions at right angles.
Two variants of the basic experiment were performed. In the first the dose
of irradiation was 500 r instead of 400 r. In the second treatment was begun
either on the day of, or 10 days after, transplantation ofthe tumour.
Propagation of the tumours
Six different tumours were used. All were spontaneous mammary carcino-
mas which developed spontaneously in A-strain female mice and were maintained
by transplantation every 2 to 3 weeks in females ofthe same strain.
One was used up to its seventh transplant generation but showed no evidence
of deletion of tumour-specific antigens (see Woodruff and Symes, 1962b); the
others were all in either their first or second transplant generation.
* Preliminary tests showed that the behaviour of the tumour in male and female recipients was
indistinguishable.
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Irradiation
The mice were irradiated in perspex boxes with a 230 kv Westinghouse
machine (15 ma., 0 5 mm. Cu + 1 mm. Al, half-value layer 1.2 mm. Cu, focus-skin
distance 75 cm.) under conditions of maximum back scatter. The dose rate was
66 r/min., measured in air at the surface of the animal nearest the tube.
Immunization of cell donors
Adult CBA mice were immunized by being given at one operation a sub-
cutaneous transplant of the A-strain tumour to each flank and a third transplant
to the peritoneal cavity in the form of an injection of tumour cell suspension.
The spleen, and the axillary and inguinal lymph nodes on each side, were removed
five days later and cell suspensions were prepared from them. Preliminary
experiments showed that following this procedure cells from the spleen were
about as effective as cells from the nodes both as regards their anti-tumour
activity and their capacity to produce graft-versus-host disease in irradiated
A-strain mice, whereas after immunization with subcutaneous transplants only
spleen cells were much less effective than cells from the nodes.
Preparation and injection of cell suspensions
Cell suspensions were prepared by cutting up the spleen or the nodes with
scissors, grinding the tissue very gently in Hanks's solution, using a hand-operated
glass homogenizer, and straining through stainless steel mesh. The cells were
spun down (200 g for 5 minutes) and resuspended in sufficient Hanks's solution
to give a total nucleated cell count of 200 million cells/ml.
Doses of 100 million to 150 million cells were given in one injection ; larger
doses were subdivided, 100-150 million cells being given morning and afternoon
for either one or two days. All injections were given slowly into a tail vein.
Administration of A-methopterin
A-methopterin (Methotrexate) was given in the form of a freshly prepared
aqueous solution by subcutaneous injection on the side of the body opposite to
the tumour. The dose was 1-5 ,ug. per g. body weight every 2 days for 6 doses.
The first dose was given 2, 4 or 6 days after the first cell injection.
RESULTS
The results of the basic experiment are summarized in Table I.
It will be seen that irradiation alone produced a temporary arrest in the
growth of the tumour, but did not alter the mean survival of the animal or the
size of the tumour at death (Fig. 1 and 2) as compared with the values obtained
in untreated controls.
Injection of 100 million isogeneic cells in addition to irradiation had no appre-
ciable effect.
Injection of 100-150 million normal allogeneic cells increased the time for
which tumour growth was arrested, and the tumour remained on average slightly
smaller than in mice which received either no treatment or irradiation alone, but
the mean survival of the animals remained the same. Injection of 600 million
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normal allogeneic cells resulted in still more prolonged arrest of tumour growth
and a slight increase in the mean survival time, but, with the exception of one
animal which survived for only 10 days, all the mice died with large, actively
growing tumours. Administration of A-methopterin, starting 4 days after the
first spleen cell injection, did not weaken the anti-tumour effect, but far from
increasing the mean survival time of the animals actually shortened it.
Tumours whose growth remained arrested following injection of normal allo-
geneic cells until the animal died all showed extensive necrosis, often with calci-
fication, and varying degrees of fibrosis. All contained viable tumour cells.
varying in amount from scattered single cells and minute clumps to small islets up
to about 1 mm. diameter. Some sections showed massive plasma cell infiltration.
Irradiation and injection of allogeneic cells from immunized donors without
other treatment had a marked inhibitory effect on the tumour and in 9 out of 15
animals growth remained completely arrested up to the time of death (Fig. 1 and
3), but the mean survival time was less than in the untreated controls. Adminis-
tration of A-methopterin starting 2, 4 or 6 days after the irradiation and cell
injection, on average slightly increased the mean survival time without weakening
the anti-tumour effect. The figures suggest that the earlier this administration
was started the greater the increase in survival and the less the damage to the
tumour, but the evidence is not sufficient to warrant a firm conclusion to this
effect.
Tumours whose growth remained arrested following injection of immune allo-
geneic cells up to the time of death again showed extensive necrosis (Fig. 3) and
varying degrees of fibrosis and plasma cell infiltration (Fig. 4 and 5). In 3 animals
no viable tumour cells could be found; the remainder showed scattered minute
clumps or small islets.
Increasing the dose of irradiation from 400 r to 500 r in mice which received
no other treatment made no significant difference to the effect on the tumour or
the survival of the animal. When irradiation was combined with the injection of
100 million normalallogeneic spleen cells, increasing the irradiation dose from 400 r
to 500 r resulted in a slightly greater effect on the tumour, as judged by the time
for which growth was arrested, but the mean survival of the animals was not
significantly altered.
With either irradiation (400 r) alone, or irradiation (400 r) combined with in-
jection of 100 million normal allogeneic spleen cells, treatment started on either
EXPLANATION OF PLATES
FIG.1. These two mice each received a tumour transplant 20 days previously. The one on the
left, which was treated by irradiation (400 r) alone, has a large tumour; the one on the
right, which was treated by irradiation and transplantation of immune allogeneic cells,
does not have a palpable tumour but shows evidence of graft-versus-host reaction.
FIG. 2. Active tumour from a mouse treated 49 days previously by irradiation only. H. and
E. x75.
FIG. 3.-Necrotic tumour from a mouse treated 16 days previously by irradiation and
transplantationofimmune allogenoic spleen cells. H. and E. x 155.
FIG. 4. Tumour from a mouse treated 15 days previously by irradiation and transplantation
of immune allogeneic cells, showing focal accumulation of plasma cells. H. and E. x 127.
FIG. 5. Higher power view of the tumour shown in Fig. 4. H. and E. x 360.
FIG. 6. Section of spleen from the same mouse as Fig. 2. Pyronin methyl-green. x 127.
FIG. 7. Section of spleen from the same mouse as Fig. 3, showing extensive necrosis due to
graft-versus-host reaction. Pyronin methyl-green. x 127.
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the day the tumour was transplanted or 10 days after this had much the same
effect as regards retardation of growth of the tumour as treatment started 5 days
after tumour transplantation. There was no significant difference in the mean
survival time of animals treated on day 5 or day 10 and the untreated controls,
but irradiation on the day of tumour transplantation reduced the mean period
of survival to 28 days, which is significantly less than that of the controls
(t = 2-90, n = 29, P < 0-01).
CONCLUSIONS AND DISCUSSION
It has been establislied that the growth of a transplanted mammary car-
cinoma may be greatly retarded, and the tumour may sometimes be completely
destroyed, by exposing the recipient to a sublethal dose ofwhole body irradiation
and then injecting allogeneic lymphoid cells. It is clear moreover that the cells
played an essential role since irradiation alone, in the dosage used, was much less
effective, whereas increasing the cell dose or using cells from immunized donors
in place of normal cells increased the period of tumour growth arrest.
It has been reported previously by Defendi and Koprowski (1959) that trans-
plantation of allogeneic lymphoid tissue to newborn hamsters reduced the
incidence of tumours following a subsequent injection of polyoma virus, and
more recently Wigzell (1961) has shown that growth of lymphoma cells trans-
planted to Fl hybrid mice from one parent strain could be inhibited by injectionl
of normal lymphoid cells from the other parent strain 5 days previously, or of
lymphoid cells from pre-immunized members of this strain at the same time as
the lymphoma cell injection. The results now reported differ in that striking
inhibition of growth was obtained with tumours of a type which appear to be
much less susceptible to immunological attack than the lymphomas, and which
had been transplanted 5 or 10 days before treatment was started.
None of the procedures tested, however, significantly increased the mean
survival of the tumour-bearing animals, and some actually shortened it, because
animals which were not killed by their tumour died instead as a result of the
treatment (Fig. 1).
Many of these deaths were undoubtedly caused by the graft-versus-host re-
action (Fig. 7. See Fig. 6 for comparison).
The possibility that some of the early deaths were due instead to rejection
of the grafted cells combined with failure of regeneration of the recipient's own
haemopoietic tissue, and were thus a manifestation of the sublethal zone effect
described by Trentin (1958), cannot be excluded on the basis of available histo-
logical findings since these reveal only the terminal picture which may be indistin-
guishable inthe two conditions; it seemsunlikely howeverin view ofthe relatively
low dose of irradiation and high dose of immunologically competent cells* used
in the present experiments.
Thetherapeutic efficiency ofthe procedure wouldbe increasedifamethod could
be found of " rescuing " the tumour-bearing animal after the foreign cells had
produced an adequate effect on the tumour, or alternatively if the attack could
* In comparing these experiments using spleen cells with those of Trentin and others in which
bone marrow was used, allowance must be made for the fact that in the spleen a much higher propor-
tion of the nucleated cells are immunologically competent, as judged by their capacity to cause
a graft-versus-host reaction.
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be " focused " in such a way as to produce relatively more damage to the tumour
and less to the host.
As mentioned in the introduction, there is evidence (Woodruff, 1962) that
administration of A-methopterin may reduce the mortality resulting from
injection oflarge doses ofCBA strain spleen cells to sublethally irradiated normal
(i.e. non-tumour bearing) A-strain mice, it therefore seemed possible that the
same procedure might be effective as a rescue procedure in the present experi-
ments, at any rate after injection of cells from non-immunized donors, but this
expectation has not been fulfilled. Another procedure, which is currently being
investigated, is the transplantation of isogeneic splenic tissue at various times
after the irradiation and injection ofallogeneic cells.
The possibility of " focusing " the immunological attack on the tumour is
also being studied. The most obvious procedure would seem to be to study the
effect of local treatment in the forms of injection of lymphoid cells and small
pieces of tissue into and around an accessible tumour, or intraperitoneally in the
case of ascites tumours. In experiments with large animals the injection might
be given into the main arterial supply of the tumour. A subtle approach to the
problem, based on a notion originally put forward by Levi, Schechtman, Sherings
and Stanley (1959) in relation to the development of anti-cancer sera, is to use
cells from animals previously made tolerant ofnormal tissue from the prospective
recipient and later immunized against the tumour.
We are plaining also to study the extent to which the accumulation of
systemically injected immunologically competent cells in a tumour is modified
by previous local treatment in the form of irradiation or injection of cytotoxic
drugs; and, conversely, to seek for methods by which accumulation of such
cells in the spleen may be prevented or reduced.
The results of these investigations will be reported later. Meanwhile it has
seemed justifiable to use normal allogeneic human spleen cells, obtainedfrom
spleens removed on account of idiopathic thrombocytopenic purpura and other
diseases, for the treatment ofpatients with advanced cancer (Woodruffand Nolan,
unpublished), and the possibility ofobtaining immune cells by mutually immuniz-
ing two such patients against each other's tumour is under consideration. The
first essential in such trials must be to avoid harm to the patient. It is necessary,
therefore, to start with a small dose of irradiation (or radiomimetic drug) and a
small dose of cells, and to increase these only in the light of accumulated clinical
experience and all the available experimental data.
SUMMARY
Experiments are described which show that the growth of a transplanted
mammary carcinoma in A-strain mice may be greatly retarded, and the tumour
may sometimes be completely destroyed, by exposing the recipient to a sublethal
dose of irradiation (capable itself of producing only a very slight effect on the
tumour) and then injecting allogeneic lymphoid cells from either a normal CBA
mouse or a CBA mouse immunized against the A-strain tumour. These pro-
cedures did not increase (and sometimes decreased) the mean survival of the
tumour-bearing animals because those which were not killed by their tumour died
as a result of the graft-versus-host reaction. Attempts to prevent this fatal
complication by administration of A-methopterin were unsuccessful, but other
possible approaches to the problem are suggested.
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